Influence of Cataract Surgery on Early DME The DICAT-II Study
DICAT-II
1 other identifier
observational
143
1 country
1
Brief Summary
To determine if cataract surgery may have an impact on the natural history of early DME (E-DME)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 9, 2019
CompletedFirst Posted
Study publicly available on registry
September 19, 2019
CompletedStudy Start
First participant enrolled
January 28, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2021
CompletedAugust 16, 2021
August 1, 2021
10 months
September 9, 2019
August 13, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Influence of cataract surgery on E-DME
Changes in central subfield thickness (CST) and/or macular volume (MV) measured by SD-OCT in eyes with E-DME during the first 4 months after cataract surgery (Group 1) compared to eyes with the same condition but without any surgical intervention (Group 2). Eyes in both groups developing a "significant worsening" of E-DME, defined as an increase of at least 50 microns in central subfield thickness (CST) or 0.5 mm3 in macular volume (MV) measured by SD-OCT will be withdrawn from the study to receive adequate therapeutic intervention.
4 months
Study Arms (2)
SURGERY
subjects with early DME undergoing cataract surgery
OBSERVATION
subjects with early DME
Interventions
Eligibility Criteria
Study Groups GROUP 1: Eyes with E-DME scheduled for cataract surgery GROUP 2: Control Group. Eyes with E-DME and clear media, non-significant cataract, pseudophakic (Group 2a: phakic; Group 2b: pseudophakic) or eyes with cataract scheduled for surgery after the end of follow up. Gold candidate: patient with bilateral E-DME and cataract in at least one eye.
You may qualify if:
- Eligible patients will be identified during the regular preoperative cataract examination. In the presence of a diabetic patient, an OCT scan will be performed (according to the protocol, see below).
- Only eyes with E-DME will be eligible for the study.
- Diabetic patients with bilateral E-DME and bilateral cataract. Both eyes will be enrolled: one eye will receive surgery at M4, the other at the end of follow up (M8) or later (gold candidate).
- Diabetic patients with bilateral E-DME and cataract in just one eye (gold candidate). The eye with E-DME and no cataract may be already pseudophakic (surgery performed at least 18 months before) or with clear media.
- Diabetic patients with E-DME and cataract in just one eye
- Diabetic patients with cataract and no E-DME in the eye scheduled for surgery but E-DME in the other eye. Only the eye with E-DME will be enrolled.
You may not qualify if:
- Past ocular surgery of any kind (except for cataract surgery) or ocular pathologies other than diabetic retinopathy.
- Macular edema considered to be due to a cause other than diabetic macular edema.
- OCT examination suggesting that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema. In the case of ERM, an OCT scan must be sent to the Coordinating Center for approval.
- Any ocular pathology or ocular condition is present (other than diabetes) that, in the opinion of the investigator, might affect macular edema
- History of any therapy (anti-VEGF treatment, focal/grid macular photocoagulation, intravitreous or peribulbar corticosteroids) for DME or diabetic retinopathy in the past 12 months.
- History of YAG capsulotomy performed within two months before enrollment.
- Aphakia.
- Evidence of uncontrolled glaucoma.
- Intraocular pressure must be \<25 mmHg, with no more than one topical glaucoma medication.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
ESASO Scientific Projects
Lugano, CH-6901, Switzerland
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Scientific Studies Coordinator
Study Record Dates
First Submitted
September 9, 2019
First Posted
September 19, 2019
Study Start
January 28, 2020
Primary Completion
November 30, 2020
Study Completion
January 31, 2021
Last Updated
August 16, 2021
Record last verified: 2021-08
Data Sharing
- IPD Sharing
- Will not share